|Description||E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.|
AZ0108 is an orally bioavailable, PARP1,2,6 inhibitor that causes a multi-polar spindle phenotype at double digit nM concentrations. AZ0108 has been utilized as...
DR 2313 has been found to be a PARP-1/PARP-2 inhibitor and could exhibit neuroprotective avtivities as well as reduce cortical infarct volume in focal ischemia.
EB 47 dihydrochloride
EB 47 dihydrochloride is a PARP-1 inhibitor (IC50 = 45 nM) that reduces infarct volume in both a rat transient middle cerebral arterial occlusion model and a ca...
RLLFT-NH is a reversed amino acid sequence control peptide for TFLLR-NH2. TFLLR-NH2 is a peptide derived from the protease-activated receptor-1 (PAR1) that acts...
OUL 35 is a PARP-10 inhibitor with IC50 value of 0.329 μM. It can rescue HeLa cells from ARTD10 induced apoptotic cell death.
INO1001 is an isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitiza...
G007-LK is a potent, "rule of 5" compliant and a metabolically stable TNKS1/2 inhibitor. G007-LK displayed high selectivity toward tankyrases 1 and 2 with bioch...
BYK 49187 is a non-selective PARP inhibitor (pIC50 = 8.36 and 7.50 for cell-free recombinant PARP-1 and murine PARP-2, respectively).